Home › Markets › Health Care › OPK

OPKO Health Inc. (OPK)

OPK trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$1.32
-4.35% on the day
Market cap
$985.2M
Small cap
Revenue · 2025
$606.9M
-14.9% on 2024
Net income · 2025
-$225.7B
-37187.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerOPK on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000944809
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$606.9M
Net income-$225.7B
Operating income-$117.4M
Net margin-37187.0%
Operating margin-19.3%
Revenue growth-14.9%
Cash$364.4M
Total assets$1.9B
P/E (computed)Net income was not positive
P/S (computed)1.6×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52019-10-25
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q/A2026-08-28
Latest current report8-K2026-10-02
Latest proxyDEFA14A2026-05-15

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-1.4%
1 month-12.7%
3 months+15.1%
Year to date+8.7%
1 year-9.3%
From 52-week high-20.8%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SVRASavara Inc.$4.78-1.24%$982.1M
MNKDMannKind Corporation$3.05-2.56%$980.7M
LTGOLatigo Biotherapeutics Inc.$15.71-1.94%$1.0B
AKTSAktis Oncology Inc.$16.64-4.04%$925.5M
JANXJanux Therapeutics Inc.$17.18-5.34%$1.1B
AVLNAvalyn Pharma Inc.$23.74-4.27%$1.1B
HROWHarrow Inc.$28.24-2.99%$1.1B
NBTXNanobiotix S.A.$21.49-8.16%$1.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier